Jean-Jacques Kiladjian

Has grant

France

Research Interests

Explore related searches

Professors in France Professors in Cancer Biology Cancer Biology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

MITHRIDATE

Open Date: 2017-06-01

Close Date: 2022-06-01

Grant: Close

CTIM-3

Open Date: 2014-02-01

Close Date: 2018-09-01

Grant: Close

Clinical investigation centre of the Saint-Louis hospital

Open Date: 2011-01-30

Close Date: 2015-01-30

Grant: Close

COSMYD - France (Collaborative Study of Myeloproliferative Disorders) - Phase II-III randomized, multicenter, adaptive scheme clinical trial comparing pegylated interferon alpha-2a (Pegasys ®) to hydroxyurea (Hydrea ®) in patients with Polycythemia Vera and high risk Essential Thrombocythemia with JAK2 V617F mutation.

Open Date: 2007-02-02

Close Date: 2010-02-02

Articles (14)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

Vikas Gupta

CANADA

View details

Srdan Verstovsek

UNITED STATES

View details

Alessandro M. Vannucchi

ITALY

View details

Aaron Gerds

Assitant Professor

Cleveland Clinic

UNITED STATES

View details

Victoria Empson

AOP Orphan Pharmaceuticals GmbH

AUSTRIA

View details

Ronald Hoffman

Medical Doctor/Professoe

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Dariusz Woszczyk

Head of Department

Opole University

POLAND

View details

haifa kathrin al-ali

University Hospital Halle (Saale)

GERMANY

View details

Steffen Koschmieder

RWTH Aachen University

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jean-Jacques Kiladjian

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (14)

Current myeloproliferative neoplasm scoring systems for clinical practice

Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis

Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape

Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies

Biological drivers of clinical phenotype in myelofibrosis

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial

An inherited gain‐of‐function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Collaborators (9)

Vikas Gupta

Srdan Verstovsek

Alessandro M. Vannucchi

Aaron Gerds

Victoria Empson

Ronald Hoffman

Dariusz Woszczyk

haifa kathrin al-ali

Steffen Koschmieder

Make your next move.